Leerink Partners Initiates Coverage On Phathom Pharmaceuticals with Market Perform Rating, Announces Price Target of $10
Benzinga Newsdesk 1 month ago
NewsInitiationAnalyst RatingsPrice Target
Leerink Partners analyst Daniel Clark initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Market Perform rating and announces Price Target of $10.
Leerink Partners analyst Daniel Clark initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Market Perform rating and announces Price Target of $10.